ClinicalTrials.gg
RecruitingNCT06552637RECOVER-HFUpdated Nov 19, 2026

Synchronized Diaphragmatic Stimulation in Symptomatic Heart Failure

An interventional study of Synchronized Diaphragmatic Stimulation in Heart Failure With Reduced Ejection Fraction, sponsored by VisCardia Inc.. Recruiting at 7 sites in 2 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-11-19.

Sponsored by VisCardia Inc. · Not applicable, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Jul 2026; still recruiting 4 months later.
Updated Nov 19, 2026Eligibility revised4 sites addedGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
270
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 2,159 studies in Heart Failure with a site in United States — 346 open to participants now, 439 under way, 27 of them phase 3. Heart Failure · United States.

Planned enrollment
395th of 1,602
270 · median 66
Started
2026
with 94 others
No phase
887 of 2,159
159 open now
Primary completion
2028-07
later than 322 of 438 live
Registered
1,931st of 2,159
by date

Among the 2,159 studies in Heart Failure with a site in United States, this one is the 395th largest by planned enrollment of the 1,602 interventional ones that give a count, is one of 95 that started in 2026, is one of 887 with no phase, reaches primary completion later than 322 of the 438 other live ones, and was the 1,931st registered.

Heart Failure

6,340 studies on the registry are indexed under Heart Failure; 1,397 are open to participants now.

Browse Heart Failure studies →

Open to participants now

346 of the 2,159 studies in Heart Failure with a site in United States are open now. Recruiting first, the newest first:

341 more — sign in →

All 346 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 968 Heart Failure studies recruiting now, 691 (71%) set no upper age limit and 90 (9%) stop at 75 or younger; 64 take children under 18; 97 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 2,159 studies in Heart Failure with a site in United States, or all of them as a file.
02

Study summary

RECOVER HF is a clinical study designed to evaluate the safety and efficacy of Synchronized Diaphragmatic Stimulation delivered using the VisONE System in the treatment of patients with heart failure.

Read the detailed description

Symptomatic Diaphragmatic Stimulation (SDS) is a novel extra-cardiac device for patients who have symptomatic heart failure. Elevated intracardiac pressures are the hallmark of heart failure (HF) and a key pathological driver of disease progression and limited exertional capacity. The degree of cardiac pressure elevation is determined by preload, afterload, and pericardial restraint. The pericardium restrains the heart, and the degree of restraint is determined by the pericardial structure itself and the intrathoracic pressure. This aspect of HF pathophysiology is among the fundamental drivers behind the SDS therapy concept. SDS induces a temporal modulation of intrathoracic pressure.. When synchronized with the cardiac cycle, SDS may improve cardiac filling, cardiovascular pressure conditions, and cardiac performance

RECOVER HF is a prospective, randomized, doubled-blinded study of Synchronized Diaphragmatic Stimulation (SDS) delivered in an imperceptible manner in subjects with heart failure defined as New York Heart Association (NYHA) functional class II/III, left-ventricular ejection fraction (LVEF) \<=40%, and QRS duration \<=130ms despite receiving the appropriate heart failure guideline directed medical therapy (GDMT). All subjects will receive an implanted VisONE System. Two-weeks post implant subjects will be randomized in a 1:1 ratio into a SDS therapy active or control (SDS therapy inactive) arm with both arms receiving GDMT. At 6 months the control arm will have SDS therapy activated with all patients receiving therapy and GDMT throughout the remainder of the study period. The study will be conducted at up to 30 investigational sites in the United States and several outside the U.S. These centers will enroll subjects with the goal of randomizing approximately 270 subjects who meet the entry criteria.

03

Conditions studied

  • Heart Failure With Reduced Ejection Fraction

Keywords

  • Heart Failure
  • Heart Disease
  • Synchronized Diaphragmatic Stimulation
  • Implantable Heart Failure Device Therapy
04

Who can participate

The criteria were revised on the registry on Oct 23, 2026. See what changed

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • classes II/III on optimal Guideline Directed Medical Therapy (GDMT) for 3 months
  • EF≤ 40%
  • At the time of consent, willing and able to comply with protocol requirements, including attending all required visits
  • Willing to participate in the study and able to sign an form
  • ≥18 years of age at the time of consent

Exclusion criteria

Exclusion Criteria:

  • Baseline 6-minute walk test > 500 meters or \< 200 meters
  • NT-proBNP\< 250 if on loop diuretics, or NT-proBNP \< 500 if not on loop diuretics
  • Supine resting heart rate > 140 bpm
  • Systolic blood pressure \< 80 mmHg or > 170 mmHg
  • Serum creatinine > 2.5 mg/dL
  • Serum hepatic function 3x
  • Any of the following within the previous 3 months: unstable angina, AMI, CABG, PTCA, CVA/, AF (episodes > 24 hours), symptomatic NSVT or DCCV
  • Any inotropic drug treatment within the previous 3 months
  • Bradycardia (heart rate \< 50 beats/min), atrial arrhythmias with rates > 100 beats/min, sustained ventricular tachycardia or frequent ventricular ectopy >10% present during screening
  • Significant uncontrolled symptomatic bradyarrhythmia, atrial fibrillation, unstable ventricular arrhythmias or frequent ventricular ectopy > 10% documented within the previous 3 months
  • Reversible non-ischemic cardiomyopathy
  • Valvular disease requiring intervention within the next 12 months or presence of significant valve disease as determined by the site cardiologist as:

    1. Greater than mild mitral valve stenosis
    2. Greater than moderate mitral valve regurgitation
    3. Greater than mild tricuspid valve stenosis
    4. Greater than moderate-severe tricuspid valve regurgitation
    5. Greater than moderate aortic stenosis
    6. Greater than moderate aortic regurgitation
    7. Greater than mild-moderate pulmonic stenosis
    8. Greater than moderate pulmonic regurgitation
  • Severe primary pulmonary disease, including pulmonary arterial hypertension. PAP sys >70 mmHg at rest
  • Severe , other respiratory or lung diseases where \< 50%
  • Presence of more than small pleural effusion or history of pleural drainage within the previous 6 months
  • Known history of diaphragmatic paralysis or suspicion confirmed by unilateral or bilateral elevation of the diaphragm on chest x-ray
  • Pericardial disease
  • Non-cardiac condition substantially impairing ambulation of 6-minute hall walk test interpretation
  • Existing diaphragmatic stimulation for respiration assist
  • Present LVAD, Baroreflex Activation Therapy, Cardiac Contractility Modulation or interatrial shunt devices; temporary mechanical cardiac assist devices (current or within the previous 3 months)
  • to laparoscopic access to the diaphragm, as determined by the implanting physician
  • Known intra-abdominal pathology which could increase the risk of laparoscopic access to the diaphragm.
  • Previous open laparotomy within 1 year
  • Previous thoracic or abdominal organ transplant
  • Drug induced immuno-suppression
  • > 40
  • Enrollment in a concurrent investigation / clinical study
  • Having a of \<1 year due to any condition
  • Pregnant or planning a pregnancy during the study period
  • Known allergies to implantable device materials
  • History of systemic infection requiring the use of intravenous antibiotics within the previous 3 months
  • Received cardiac resynchronization therapy (CRT) within six months of randomization, or is actively receiving CRT
  • Currently have a Class I indication for a cardiac resynchronization therapy (CRT) device according to AHA/ACC/ESC guidelines for the treatment of congestive heart failure
Terms in these criteria, in plain language(9)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

TIA (transient ischaemic attack)

A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.

Stroke symptoms need emergency care at once, even if they go away.

COPD

Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.

FEV1

From a breathing test (spirometry): how much air you can blow out in the first second. Often given as a percentage of what is expected for your age, height and sex.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
270 participants (estimated)

Study arms

  • Experimental
    Device and Medical Management

    * Subjects will be implanted with the VisONE System programmed to deliver SDS (Therapy On) and receive optimal, stable, Guideline Directed Medical Therapy (GDMT) for heart failure (American Heart Association \[AHA\] / American College of Cardiology \[ACC\] guidelines) including those drugs to be determined by the subject's physician * Assigned Interventions: * Device: VisONE System (SDS) * Drug: Medical Management

    Device: Synchronized Diaphragmatic Stimulation

  • Sham comparator
    Medical Management

    * Subjects will be implanted with the VisONE System programmed not to deliver SDS (Therapy Off) and receive optimal, stable, Guideline Directed Medical Therapy (GDMT) for heart failure (American Heart Association \[AHA\] / American College of Cardiology \[ACC\] guidelines) including those drugs to be determined by the subject's physician * Assigned Interventions: * Drug: Medical Management

    Device: Synchronized Diaphragmatic Stimulation

Interventions

  • DeviceSynchronized Diaphragmatic Stimulation

    Implantable Pulse Generator system providing cardiac-gaited stimulation of the diaphragm and thereby influence cardiovascular properties relevant in heart failure.

    Also known as: Asymptomatic Diaphragmatic Stimulation, SDS, ADS, VisONE SDS

06

What researchers measure

Primary outcomes

  1. Left ventricular End-Systolic Volume (LVESV)

    To demonstrate that treatment with the VisONE System (SDS) plus GDMT results in a larger percent improvement in LVESV at 6 months post-randomization from baseline than medical management alone.

    Time frame: 6 months

  2. Six Minute Hall Walk (6MHW)

    To demonstrate that treatment with the VisONE System (SDS) plus GDMT results in a larger improvement in 6MHW at 6 months post-randomization from baseline than medical management alone.

    Time frame: 6 months

  3. Minnesota Living with Heart Failure quality of Life Score (MLWHF QOL)

    To demonstrate that treatment with the VisONE System (SDS) plus GDMT results in a larger improvement in MLWHF QOL at 6 months post-randomization from baseline than medical management alone.

    Time frame: 6 months

  4. Major Adverse Respiratory and Cardiovascular Events (MARCE)

    To demonstrate the safety of the VisONE System by analyzing Major Adverse Respiratory and Cardiovascular Events (MARCE) occurring within 6 months post implant for the rate, severity and association with the device or procedure (goal \>70% freedom): * Cardiovascular Death * Stroke * Cardiac Arrest * Interaction with cardiac rhythm device requiring permanent termination of SDS therapy * Acute Heart Failure Decompensation * Infection requiring device/lead explant * Diaphragmatic dysfunction leading to a clinically significant reduction is respiratory function * Inadequate SDS therapy delivery requiring surgical intervention * Injury to abdominal organs requiring surgical intervention * Pneumothorax * Hemothorax

    Time frame: 6 months

Secondary outcomes

  1. Left Ventricular Ejection Fraction (LVEF)

    To demonstrate that treatment with the VisONE System (SDS) plus GDMT results in a larger improvement in LVEF at 6 months post-randomization from baseline than medical management alone.

    Time frame: 6 months

  2. N-Terminal Pro Brain Natriuretic Peptide (NT-proBNP)

    To demonstrate that treatment with the VisONE System (SDS) plus GDMT results in a larger reduction in NT-proBNP (log-10 transformed) at 6 months post-randomization from baseline than medical management alone.

    Time frame: 6 months

  3. Left ventricular End-Systolic Volume (LVESV)

    To demonstrate that treatment with the VisONE System (SDS) plus GDMT results in a larger percent improvement in LVESV at 12 months post-randomization from baseline than medical management alone.

    Time frame: 12 months

  4. Six Minute Hall Walk (6MHW)

    To demonstrate that treatment with the VisONE System (SDS) plus GDMT results in a larger improvement in 6MHW at 12 months post-randomization from baseline than medical management alone.

    Time frame: 12 months

  5. Minnesota Living with Heart Failure quality of Life Score (MLWHF QOL)

    To demonstrate that treatment with the VisONE System (SDS) plus GDMT results in a larger improvement in MLWHF QOL at 12 months post-randomization from baseline than medical management alone.

    Time frame: 12 months

  6. Left Ventricular Ejection Fraction (LVEF)

    To demonstrate that treatment with the VisONE System (SDS) plus GDMT results in a larger improvement in LVEF at 12 months post-randomization from baseline than medical management alone.

    Time frame: 12 months

  7. N-Terminal Pro Brain Natriuretic Peptide (NT-proBNP)

    To demonstrate that treatment with the VisONE System (SDS) plus GDMT results in a larger reduction in NT-proBNP (log-10 transformed) at 12 months post-randomization from baseline than medical management alone.

    Time frame: 12 months

07

Study locations

7 of 7 sites recruiting
  • Ascension St. Vincent Hospital
    Indianapolis, Indiana 46260, United States
    Recruiting
  • Saint Francis Hospital
    Tulsa, Oklahoma 74136, United States
    Recruiting
    • Ralph D Ensley, MD · Contact(918) 494-8500
    • Ralph D Ensley, MD · Principal investigator
  • University of Pennsylvania
    Philadelphia, Pennsylvania 19104, United States
    Recruiting
    • Aditya Parikh, MD · Contact(215) 615-4949
    • Aditya Parikh, MD · Principal investigator
  • Baylor College of Medicine
    Houston, Texas 77030, United States
    Recruiting
    • Ajith Nair, MD · Contactajith.nair@bcm.edu · (713) 798-6230
    • Ajith Nair, MD · Principal investigator
  • Tbilisi Heart and Vascular Clinic
    Tbilisi, 0159, Georgia
    Recruiting
    • Tamaz Shaburishvili, MD · Contact0322 157 159
    • Tamaz Shaburishvili, MD · Principal investigator
  • Jo Ann University Hospital
    Tbilisi, Georgia
    Recruiting
  • New Hospitals
    Tbilisi, Georgia
    Recruiting
    • Lasha Mosiashvili, MD · Contactlashamose@gmail.com · +995 599 481 800
    • Lasha Mosiashvili, MD · Principal investigator
08

Timeline

5 registry updates since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jul 2026 (actual). Primary completion is estimated for Jul 2028, 24 months after the start.

Of 236 industry-sponsored interventional studies with no phase under Heart Failure, half reached primary completion within 34 months of starting (the median), counting those still running; a quarter within 18 and three quarters within 61. This study's planned 24 months is below that.

Counting every sponsor, half of 1,355 studies reached it within 31 months; a quarter within 16 and three quarters within 52.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 6, 2024
First posted
Aug 14, 2024
StartActual
Jul 8, 2026
Primary completionEst.
Jul 2028
CompletionEst.
Dec 2029
Last update
Nov 19, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Sites
4 sites added
Show 4 added (2 United States, 2 Georgia)
  • Baylor College of Medicine · Houston, United States
  • Ascension St. Vincent Hospital · Indianapolis, United States
  • New Hospitals · Tbilisi, Georgia
  • Jo Ann University Hospital · Tbilisi, Georgia
across 4 updates, Oct 6, 2026 – Nov 19, 2026
Eligibility
1 inclusion criterion edited, 3 added, 1 removed; 4 exclusion criteria edited, 3 added, 1 removed
What changed in the criteria
Inclusion criteria
  • EditedNYHA classes II/III on optimal Guideline Directed Medical Therapy (GDMT) for 3 months
  • RemovedQRS duration ≤ 130 ms
  • AddedAt the time of consent, willing and able to comply with protocol requirements, including attending all required visits
  • AddedWilling to participate in the study and able to sign an informed consent form
  • Added≥18 years of age at the time of consent
Exclusion criteria
  • EditedBaseline 6 -minute walk test > 500 meters or < 200 meters
  • EditedAny of the following within the previous 3 months: unstable angina, AMI, CABG, PTCA, CVA/TIA, persistent AF (episodes > 24 hours), symptomatic NSVT or DCCV
  • EditedSevere COPD, other respiratory or lung diseases where FEVFEV1 < 50%
  • RemovedDiabetic neuropathy
  • AddedNon-cardiac condition substantially impairing ambulation of 6-minute hall walk test interpretation
  • EditedPresent LVAD, Baroreflex Activation Therapy, Cardiac Contractility Modulation or interatrial shunt devices; temporary mechanical cardiac assist devices (current or within the previous 3 months); or CRT that is indicated or implanted and functional
  • AddedReceived cardiac resynchronization therapy (CRT) within six months of randomization, or is actively receiving CRT
  • AddedCurrently have a Class I indication for a cardiac resynchronization therapy (CRT) device according to AHA/ACC/ESC guidelines for the treatment of congestive heart failure
Oct 23, 2026
Show all 5 updates
  1. Nov 19, 2026
    1 site added
    Show site
    • Jo Ann University Hospital · Tbilisi, Georgia
  2. Nov 13, 2026
    1 site added
    Show site
    • New Hospitals · Tbilisi, Georgia
    + 1 other change: verification date
  3. Oct 23, 2026
    Eligibility 1 inclusion criterion edited, 3 added, 1 removed; 4 exclusion criteria edited, 3 added, 1 removed
    What changed in the criteria
    Inclusion criteria
    • EditedNYHA classes II/III on optimal Guideline Directed Medical Therapy (GDMT) for 3 months
    • RemovedQRS duration ≤ 130 ms
    • AddedAt the time of consent, willing and able to comply with protocol requirements, including attending all required visits
    • AddedWilling to participate in the study and able to sign an informed consent form
    • Added≥18 years of age at the time of consent
    Exclusion criteria
    • EditedBaseline 6 -minute walk test > 500 meters or < 200 meters
    • EditedAny of the following within the previous 3 months: unstable angina, AMI, CABG, PTCA, CVA/TIA, persistent AF (episodes > 24 hours), symptomatic NSVT or DCCV
    • EditedSevere COPD, other respiratory or lung diseases where FEVFEV1 < 50%
    • RemovedDiabetic neuropathy
    • AddedNon-cardiac condition substantially impairing ambulation of 6-minute hall walk test interpretation
    • EditedPresent LVAD, Baroreflex Activation Therapy, Cardiac Contractility Modulation or interatrial shunt devices; temporary mechanical cardiac assist devices (current or within the previous 3 months); or CRT that is indicated or implanted and functional
    • AddedReceived cardiac resynchronization therapy (CRT) within six months of randomization, or is actively receiving CRT
    • AddedCurrently have a Class I indication for a cardiac resynchronization therapy (CRT) device according to AHA/ACC/ESC guidelines for the treatment of congestive heart failure
  4. Oct 8, 2026
    1 site added
    Show site
    • Ascension St. Vincent Hospital · Indianapolis, United States
    + 1 other change: contact details
  5. Oct 6, 2026
    1 site added
    Show site
    • Baylor College of Medicine · Houston, United States
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

09

Registry details

Key details

Study ID
NCT06552637
Lead sponsor
VisCardia Inc.
Collaborators
Clinical Accelerator, Duke Clinical Research Institute
Responsible party
Sponsor
First posted
Aug 14, 2024
Start date
Jul 8, 2026
Primary completion
Jul 2028 (estimated)
Completion
Dec 2029 (estimated)
Last update
Nov 19, 2026

Study contacts

Calvin Flowers
Contact
flowersc@viscardia.com
(503) 431-3823
Joelle Duker
Contact
dukerj@viscardia.com
(503) 431-3800
Lee R Goldberg, MD
principal investigator · University of Pennsylvania

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
Yes
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion